Top Industry Leaders in the Rheumatoid arthritis Market
MyMD receives FDA approval for a Phase 2 clinical trial of MYMD-1, a potential oral medication for RA, marking a significant step towards a first-in-class oral treatment option.
Bristol-Myers Squibb's TYVYTUS® (sirukumab) wins FDA approval for the treatment of active ankylosing spondylitis, expanding its reach beyond RA and offering patients another therapeutic option.
Eli Lilly's Olumiant® (baricitinib) demonstrates positive results in Phase 3 trial for axial spondyloarthritis, potentially expanding its application beyond RA and demonstrating its promising efficacy in related inflammatory conditions.
AbbVie and Genentech form a collaboration to develop and commercialize JAK inhibitors for autoimmune diseases, combining their expertise and pipeline to accelerate research and development efforts.
Pfizer enters a strategic partnership with BioXcel Therapeutics to develop novel treatments for immune-mediated diseases, including RA, leveraging BioXcel's expertise in AI-powered drug discovery.
List of Rheumatoid arthritis Key Companies in the Market
- Pfizer Inc (U.S)
- Eli Lilly and Company (U.S)
- Bristol-Myers Squibb Company (U.S)
- Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Vertex Pharmaceuticals Incorporated (U.S)
- Sanofi (France)
- Cipla Ltd. (India)
- AstraZeneca (U.K)
